ArticleNeuropsychiatric disease and treatment2026
Parallel Single-Tissue Summary-Data Mendelian Randomization and Functional Validation Identify the ARRDC1 Promoter SNP rs4494021 as a Genetic Marker Associated with Anxiety Disorders.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Abnormal resting-state functional connectivity in anhedonia: A systematic review and meta-analysis.Brain imaging and behavior · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Anxiety disorders are highly heritable, but their underlying genetic mechanisms remain poorly understood. This study aimed to identify and functionally characterize genes whose expression is causally linked to anxiety disorder risk by integrating the parallel single-tissue genetic data. Methods: We applied a parallel single-tissue summary-data-based Mendelian randomization (SMR) approach. This integrated large-scale anxiety disorder GWAS statistics with expression quantitative trait loci (eQTL) data from peripheral blood and 13 brain regions. The functional impact of a prioritized SNP (rs4494021) was tested via dual-luciferase reporter assay. The behavioral consequences were investigated by performing stereotaxic, lentivirus-mediated overexpression of ARRDC1 specifically in the mouse cerebellar hemisphere, followed by comprehensive behavioral testing. Results: The SMR analysis identified thirteen potential causal genes (ITIH3, ZKSCAN4, GNL3, SLC35C1, FNBP4, COPZ1, ATP5MC1, ITIH4, EHMT1, PTPMT1, ARRDC1, NEK4, and BTN3A2). Among them, ARRDC1 emerged as a significant gene, showing associations with anxiety disorders in blood, cerebellar hemisphere, and cerebellum. The risk allele of the promoter SNP rs4494021 significantly enhanced ARRDC1 transcriptional activity. Crucially, cerebellar overexpression of ARRDC1 in mice robustly induced anxiety-like behaviors, including reduced exploration in the open field test, decreased open-arm activity in the elevated plus maze, and increased avoidance in the light-dark box test. Conclusion: By bridging genetic epidemiology with molecular and behavioral validation, this study identifies ARRDC1 promoter SNP rs4494021 as a genetically associated marker for anxiety disorders and functionally validates that elevated cerebellar ARRDC1 expression contributes to anxiety pathogenesis. These findings establish ARRDC1 as a functionally supported risk gene and highlight a novel component of anxiety-related neurocircuitry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.